CMS last week finalized its decision to cover CAR-T cell treatments, as well as all services related to administration of the costly therapies. Available CAR-T therapies have been slow to pick up coverage due to their high list prices, with Gilead’s Yescarta priced at $373,000 and Novartis’ Kymriah at $475,000. CMS currently facilitates coverage for 33,301,406 people through Medicare fee-for-service.

Source: AIS’s Directory of Health Plans